Frank de Vries


Prof. Frank de Vries started a PhD in pharmaco-epidemiology at Utrecht University in 2002 on side effects of use of inhaled corticosteroids. Since then, he has worked for the Medicine and Healthcare products Regulatory Agency. He has obtained several research grants and prizes, including the Swierenga award for respiratory disease, an NWO Veni grant and the Kohn prize from the UK National Osteoporosis Foundation. His work has been published in various journals including JAMA, the NEJM and BMJ. He is on secondment at the Utrecht Institute for Pharmaceutical Sciences, the Netherlands. He is a visiting scientist at the MRC Lifecourse Epidemiology Unit in Southampton, UK. Frank works as a hospital pharmacist in the Maastricht UMC+,

Frank’s current research activities mainly focus on effects of drugs in patients with diabetes mellitus and movement disorders. As the department’s head of research, he oversees other research lines on personalised medicine in the areas of lung oncology and psychiatric disorders.

Department of Clinical Pharmacy & Toxicology
P. Debyelaan 25, 6229 HX Maastricht 
PO Box 5800, 6202 AZ Maastricht
T: +31(0)43 387 18 81

  • 2021
    • Huckriede, J., de Vries, F., Hultstroem, M., Wichapong, K., Reutelingsperger, C., Lipcsey, M., de Frutos, P. G., Frithiof, R., & Nicolaes, G. A. F. (2021). Histone H3 Cleavage in Severe COVID-19 ICU Patients. Frontiers in Cellular and Infection Microbiology, 11, [694186].
    • van Dalem, J., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. C. G. J. (2021). Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology.
    • Houghton, R., van den Bergh, J., Law, K., Liu, Y., & de Vries, F. (2021). Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders. Autism Research, 14(8), 1800-1814.
    • Dalem, J. V., Brouwers, M. C. G. J., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., Vries, F. D., & Driessen, J. H. M. (2021). Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study. Diabetes Research and Clinical Practice, 176, [108828].
    • Abtahi, S., Driessen, J. H. M., Burden, A. M., Souverein, P. C., van den Bergh, J. P., van Staa, T. P., Boonen, A., & de Vries, F. (2021). Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study. Annals of the Rheumatic Diseases, 80(4), 423-431.
    • Bultink, I. E. M., de Vries, F., van Vollenhoven, R. F., & Lalmohamed, A. (2021). Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology, 60(1), 207-216.
    • Rasmussen, N. H., Dal, J., den Bergh, J. V., de Vries, F., Jensen, M. H., & Vestergaard, P. (2021). Increased risk of falls, fall-related injuries and fractures in people with type 1 and type 2 diabetes - a nationwide cohort study. Current Drug Safety, 16(1), 52-61.
    • Werkman, N. C. C., Nielen, J. T. H., van den Bergh, J. P. W., Ejskjaer, N., Røikjer, J., Schaper, N. C., Rossi, B., Klungel, O., Vestergaard, P., de Vries, F., & Driessen, J. H. M. (2021). Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation. Current Drug Safety, 16(1), 62-72.
  • 2020
    • Meenks, S., le Noble, J., Foudraine, N., de Vries, F., & Janssen, P. (2020). Liquid Chromatography-Tandem Mass Spectrometry to Monitor Unbound and Total Ceftriaxone in Serum of Critically Ill Patients. Current Clinical Pharmacology.
    • Al-Mashhadi, Z., Viggers, R., Fuglsang-Nielsen, R., de Vries, F., van den Bergh, J. P., Harsløf, T., Langdahl, B., Gregersen, S., & Starup-Linde, J. (2020). Glucose-Lowering Drugs and Fracture Risk-a Systematic Review. Current Osteoporosis Reports, 18(6), 737-758.